Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial.
Conclusion: Rivaroxaban did not show noninferiority to dose-adjusted VKAs for thrombotic APS and, in fact, showed a non-statistically significant near doubling of the risk for recurrent thrombosis.
Primary Funding Source: Bayer Hispania.
PMID: 31610549 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - Category: Internal Medicine Authors: Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, Vidal X, Riera-Mestre A, Castro-Salomó A, Cuquet-Pedragosa J, Ortiz-Santamaria V, Mauri-Plana M, Solé C, Cortés-Hernández J Tags: Ann Intern Med Source Type: research
More News: Antiphospholipid Syndrome | Bleeding | Cardiology | Cardiovascular | Clinical Trials | Heart | Hughes Syndrome | Internal Medicine | Spain Health | Statistics | Stroke | Thrombosis | Vitamin K | Vitamins